Physician profile
Michael E Horn
NPI 1730105099
$421.06
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.50 · 2020: $162 · 2021: $160 · 2023: $58.39 · 2024: $29.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $119.14 | 2020-2023 | Darzalex |
| Merck Sharp & Dohme LLC | $43.55 | 2020-2021 | |
| Pfizer INC. | $36.76 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $36.52 | 2020-2021 | |
| Seagen INC. | $28.07 | 2020-2021 | |
| Myriad Genetic Laboratories, INC. | $22.88 | 2023 | Myrisk |
| Amgen INC. | $22.53 | 2021 | |
| Genzyme Corporation | $19.63 | 2021 | |
| Astellas Pharma US INC | $18.61 | 2023 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $16.91 | 2020 | |
| Foundation Medicine, INC. | $15.76 | 2020 | |
| Beigene USA, INC. | $15.18 | 2024 | Brukinsa |
| Upsher-Smith Laboratories LLC | $14.26 | 2020 | |
| Puma Biotechnology, INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.